

# Veronika Bachanova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6857553/publications.pdf>

Version: 2024-02-01

185  
papers

8,655  
citations

70961

41  
h-index

48187

88  
g-index

186  
all docs

186  
docs citations

186  
times ranked

9285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
2	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1853-1862.	6.3	633
3	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	0.6	357
4	PD-1 blockade for relapsed lymphoma postâ€“allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	0.6	214
5	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
6	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
7	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018, 132, 2639-2642.	0.6	172
8	Allogeneic natural killer cells for refractory lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1739-1744.	2.0	166
9	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980.	2.5	164
10	Clinical utility of natural killer cells in cancer therapy and transplantation. <i>Seminars in Immunology</i> , 2014, 26, 161-172.	2.7	154
11	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
12	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. <i>Leukemia</i> , 2014, 28, 658-665.	3.3	121
13	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
14	Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. <i>Blood</i> , 2009, 113, 2902-2905.	0.6	106
15	Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. <i>Blood</i> , 2010, 115, 5041-5052.	0.6	98
16	NK Cells in Therapy of Cancer. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 133-141.	0.2	98
17	Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptorâ€“Negative Natural Killer Cells after NKG2A and LIR-1 Blockade. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 612-621.	2.0	87
18	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	1.3	86

#	ARTICLE	IF	CITATIONS
19	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
20	Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. <i>Haematologica</i> , 2014, 99, 322-328.	1.7	79
21	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
22	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 483-494.	2.0	74
23	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480.	0.8	74
24	Pediatricâ€inspired therapy compared to allografting for Philadelphia chromosomeâ€negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016, 91, 322-329.	2.0	72
25	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
26	Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. <i>Blood Advances</i> , 2019, 3, 897-907.	2.5	64
27	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
28	Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 1267-1272.	3.2	60
29	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
30	Diffuse large Bâ€cell lymphoma with primary treatment failure: Ultraâ€high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
31	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
32	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
33	The addition of sirolimus to the graftâ€versusâ€host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
34	GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19â€TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE Bâ€CELL LYMPHOMA (DLBCL)â€AN INTERIM ANALYSIS. <i>Hematological Oncology</i> , 2017, 35, 27-27.	0.8	52
35	Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 963-968.	2.0	48
36	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	2.5	48

#	ARTICLE	IF	CITATIONS
37	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	2.0	46
38	A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1416-1423.	1.3	45
39	A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 1599-1599.	0.6	45
40	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44
41	Hodgkin Lymphoma in Pregnancy. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 211-217.	1.2	43
42	Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells. <i>Oncotarget</i> , 2017, 8, 34453-34467.	0.8	42
43	Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1497-1504.	2.0	41
44	Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1602-1607.	2.0	41
45	Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1110-1116.	2.0	40
46	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
47	Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 237-244.	1.3	37
48	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
49	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015, 50, 197-203.	1.3	37
50	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
51	Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 138-142.	2.0	36
52	Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. <i>Bone Marrow Transplantation</i> , 2008, 41, 455-464.	1.3	34
53	Evidence-Based Guidelines An Introduction. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 26-30.	0.9	32
54	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1025-1032.	2.0	32

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
56	Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. <i>Blood Reviews</i> , 2020, 40, 100640.	2.8	32
57	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1725-1730.	2.0	31
58	Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 94-102.	0.4	31
59	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 395, 225-243.	0.7	28
60	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
61	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684.	0.6	28
62	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
63	Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460.	2.0	27
64	Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. <i>Journal of Immunotherapy</i> , 2019, 42, 65-72.	1.2	27
65	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2020, 10, 33.	2.8	26
66	Activated Notch Supports Development of Cytokine Producing NK Cells Which Are Hyporesponsive and Fail to Acquire NK Cell Effector Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 183-194.	2.0	24
67	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	0.6	24
68	How Is Hodgkin Lymphoma in Pregnancy Best Treated?. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 33-34.	0.9	23
69	<sc>C</sc>MYC</sc>-positive relapsed and refractory, diffuse large <sc>B</sc>-cell lymphoma: Impact of additional <sc>B</sc>-hits and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	2.0	23
70	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
71	Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 8-8.	0.6	22
72	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21

#	ARTICLE	IF	CITATIONS
73	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
74	Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 114-121.	0.2	20
75	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. <i>Blood</i> , 2015, 126, 3172-3172.	0.6	20
76	Hematopoietic cell transplantation for Waldenström macroglobulinemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 330-336.	1.3	19
77	Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 64-70.	2.0	19
78	Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. <i>Toxins</i> , 2018, 10, 32.	1.5	19
79	Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 358-364.	0.6	18
80	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
81	Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 5261-5263.	0.6	15
82	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	0.6	15
83	DL-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose. <i>Blood</i> , 2016, 128, 620-620.	0.6	15
84	A Case of Nonleukemic Myeloid Sarcoma With FIP1L1-PDGFR $\alpha$ Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 147-151.	2.1	14
85	Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 679-682.	1.3	14
86	Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DL-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1533-1533.	0.6	14
87	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 618-622.	2.0	13
88	Mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. <i>Journal of Community and Supportive Oncology</i> , 2016, , 351-358.	0.1	13
89	Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 944-948.	2.0	12
90	Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 310.e1-310.e6.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. <i>British Journal of Haematology</i> , 2012, 156, 273-275.	1.2	11
92	Role of allogeneic stem cell transplantation in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 290-297.	1.1	11
93	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. <i>Leukemia and Lymphoma</i> , 2017, 58, 1702-1710.	0.6	10
94	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
95	Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade. <i>Blood</i> , 2008, 112, 2906-2906.	0.6	10
96	The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 673-673.	0.6	10
97	Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. <i>Bone Marrow Transplantation</i> , 2017, 52, 697-703.	1.3	9
98	Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. <i>American Journal of Hematology</i> , 2017, 92, E529-E533.	2.0	9
99	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e20-e25.	2.0	9
100	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
101	Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors. <i>Biomolecules</i> , 2020, 10, 956.	1.8	9
102	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
103	Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 949-954.	2.0	8
104	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	0.6	8
105	Results of a Phase 1 Trial of GdA-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-6.	0.6	8
106	Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. <i>Seminars in Hematology</i> , 2016, 53, 203-208.	1.8	7
107	Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 571-574.	2.0	7
108	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7

#	ARTICLE	IF	CITATIONS
109	Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 84.e1-84.e5.	0.6	7
110	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
111	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. <i>Bone Marrow Transplantation</i> , 2021, 56, 1373-1380.	1.3	7
112	Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 1163-1163.	0.6	7
113	Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy. <i>Blood</i> , 2021, 138, 230-230.	0.6	7
114	Human Herpesvirus 6 is Associated with Status Epilepticus and Hyponatremia after Umbilical Cord Blood Transplantation. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 170-172.	0.7	6
115	High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 184.e1-184.e8.	0.6	6
116	Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1925-1931.	2.0	5
117	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 983-988.	2.0	5
118	Consolidative Radiotherapy After Autologous Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 65-73.	0.2	5
119	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multicenter analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	0.8	5
120	Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy. <i>BMJ Open</i> , 2016, 6, e011729.	0.8	5
121	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLEUCCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 308-310.	0.8	4
122	MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). <i>Hematological Oncology</i> , 2019, 37, 405-407.	0.8	4
123	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	2.8	4
124	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. <i>Leukemia and Lymphoma</i> , 2013, 54, 174-176.	0.6	3
125	Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 142-144.	1.3	3
126	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3



#	ARTICLE	IF	CITATIONS
127	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
128	Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 773.e1-773.e8.	0.6	3
129	A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 4307-4307.	0.6	3
130	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. <i>Blood</i> , 2015, 126, 4375-4375.	0.6	3
131	Results of a Phase 1 Trial of Gd-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 777-777.	0.6	3
132	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 878-878.	0.6	3
133	Why Waldenström macroglobulinemia is not just another indolent lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 95-98.	0.7	2
134	Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance?. <i>Leukemia and Lymphoma</i> , 2016, 57, 1988-1990.	0.6	2
135	Successful treatment of two cases of classical Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis with R-CEPP. <i>Leukemia and Lymphoma</i> , 2017, 58, 478-481.	0.6	2
136	BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. <i>Bone Marrow Transplantation</i> , 2017, 52, 491-493.	1.3	2
137	Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro". <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S10-S15.	0.2	2
138	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. <i>Hematological Oncology</i> , 2019, 37, 505-507.	0.8	2
139	Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 272-277.	2.0	2
140	Prognostic factors for clinical outcomes of patients with central nervous system leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 14, 240-245.	0.6	2
141	Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2966-2966.	0.6	2
142	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. <i>Blood</i> , 2018, 132, 71-71.	0.6	2
143	Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival.. <i>Blood</i> , 2012, 120, 3092-3092.	0.6	2
144	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. <i>Blood</i> , 2016, 128, 503-503.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. <i>Journal of Clinical Oncology</i> , 2015, 33, 8519-8519.	0.8	2
146	Severe hyperammonemia in chimeric antigen receptor T cells recipient—unusual differential diagnosis of encephalopathy syndrome. <i>Bone Marrow Transplantation</i> , 2022, 57, 286-288.	1.3	2
147	Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7. <i>Blood</i> , 2021, 138, 3854-3854.	0.6	2
148	Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 543-549.	1.1	2
149	Vancomycin plus Imipenem, Ceftazidime or Ciprofloxacin in Second Line Therapy in Patients with Febrile Neutropenia Not Responding to First Line Therapy. <i>Chemotherapy</i> , 1996, 42, 146-149.	0.8	1
150	Uncovering the Recovery of Natural Killer Cells after Reduced-Intensity Conditioning Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 383-384.	2.0	1
151	One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	1.2	1
152	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	0.6	1
153	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
154	HCT related toxicities and mortality in frail recipients. <i>Journal of Clinical Oncology</i> , 2019, 37, e18534-e18534.	0.8	1
155	Novel cell and immune engagers in optimizing tumor specific immunity post autologous transplant in multiple myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 61-61.	0.6	1
156	Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1587-1587.	0.6	1
157	Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S46.	2.0	0
158	Serum biomarkers TARC and IL-6 predict relapse risk in Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation. <i>Hematological Oncology</i> , 2017, 35, 323-324.	0.8	0
159	OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. <i>Hematological Oncology</i> , 2019, 37, 408-410.	0.8	0
160	Prolonged Survival in Adults with Acute Lymphoblastic Leukemia (ALL) Following Reduced Intensity Conditioning and Allogeneic Transplantation. <i>Blood</i> , 2008, 112, 4415-4415.	0.6	0
161	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Similar Efficacy of Non-Myeloablative and Myeloablative Conditioning; Long-Term Evaluation From the University of Minnesota. <i>Blood</i> , 2009, 114, 3385-3385.	0.6	0
162	Allogeneic Donor NK Cell Infusion and IL-2 for Patients with Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2009, 114, 3036-3036.	0.6	0

#	ARTICLE	IF	CITATIONS
163	The Management of Hodgkin Lymphoma During Pregnancy. , 2011, , 241-248.		0
164	IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,. Blood, 2011, 118, 3611-3611.	0.6	0
165	Unrelated Cord Blood Transplantation (UCBT) in Adult and Pediatric Acute Lymphoblastic Leukemia: Impact of Minimal Residual Disease on Relapse and Survival,. Blood, 2011, 118, 4114-4114.	0.6	0
166	Positive Positron Emission Tomography (PET) Scan in Non-Hodgkin Lymphoma Pre-Transplant Had No Impact On Relapse and Survival After Allogeneic Transplantation. Blood, 2012, 120, 1999-1999.	0.6	0
167	The Management of Hodgkin Lymphoma During Pregnancy. Hematologic Malignancies, 2015, , 297-305.	0.2	0
168	Remission Induction in a Phase I Study of a Bispecific Single Chain Immunotoxin Targeting CD22 and CD19 (DT2219) for Refractory B-Cell Malignancies. Blood, 2014, 124, 3098-3098.	0.6	0
169	Transplantation Related Toxicity and Mortality in Older Autologous Hematopoietic Cell Transplantation Recipients. Blood, 2014, 124, 3965-3965.	0.6	0
170	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. Blood, 2016, 128, 513-513.	0.6	0
171	Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab. Blood, 2016, 128, 3030-3030.	0.6	0
172	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. Blood, 2016, 128, 103-103.	0.6	0
173	Cord Blood Transplants for Lymphoid Malignancies in Adults. , 2017, , 181-189.		0
174	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4153-4153.	0.6	0
175	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. Blood, 2019, 134, 5891-5891.	0.6	0
176	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). Blood, 2019, 134, 2009-2009.	0.6	0
177	The Management of Hodgkin Lymphoma During Pregnancy. Hematologic Malignancies, 2020, , 325-334.	0.2	0
178	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. Blood, 2021, 138, 1811-1811.	0.6	0
179	Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment. Blood, 2021, 138, 1744-1744.	0.6	0
180	Factors Associated with Catheter-Related Thrombosis in Autologous Stem Cell Transplant Patients: Can We Predict Risk?. Blood, 2020, 136, 28-29.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. Blood, 2020, 136, 24-26.	0.6	0
182	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. Blood, 2020, 136, 4-6.	0.6	0
183	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 44-46.	0.6	0
184	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 47-48.	0.6	0
185	The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49.	0.6	0